Key facts
- This page summarizes Christopher Mehlin David's Form 4 filing for Novo Integrated Sciences, Inc. (NVOS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Sep 2024, 06:05.
Christopher Mehlin David - 16 Jan 2024 Form 4 Insider Report for Novo Integrated Sciences, Inc. (NVOS)
- Reporting relationship
- Chief Operating Officer, Director
- Issuer ticker
- NVOS
- Reported as of
- 16 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Sep 2024, 06:05:09 UTC
- Prior SEC filing
- 02 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher David
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher Mehlin David filed Form 4 for Novo Integrated Sciences, Inc. (NVOS) on 12 Sep 2024.
Change
- Previous filing in this sequence was filed on 02 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NOVO
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 8,195
- Date
- 16 Jan 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NOVO
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 16 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $0.7800
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents the grant, by the issuer's Board of Directors, of an option to purchase 200,000 shares of the issuer's common stock at an exercise price of $0.78 per share. The option was fully vested and exercisable on the date of grant and is exercisable until January 16, 2030.